The National Institute for Health and Care Excellence has now approved capivasertib for use on the NHS - we look at who could ...

A clinical trial that looked into the effects of the new pill plus fulvestrant, a hormone therapy, found that the treatment ...

AKT inhibitor Truqap (capivasertib) has been cleared by NICE for use in combination with standard therapy fulvestrant for ...

The outlook for someone with PIK3CA-related overgrowth spectrum (PROS) depends on factors that vary from person to person. Early intervention and treatment can improve the outlook and prevent ...

Landmark moment’ as new pill approved for common type of advanced breast cancer - The Institute of Cancer Research, London, ...

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday recommended that the National Health Service make AstraZeneca's AKT pathway inhibitor Truqap (capivasertib) with ...

Today, we've recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Aspirin use in patients with PIK3CA-mutated colorectal cancer reduces recurrence risk by over 50%. | Drug Discovery And Development ...

The PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is on track to report topline data in Q2 2025VIKTORIA-2 Phase 3 ...

PIK3CA-related overgrowth spectrum (PROS) is a rare genetic disorder that causes uncontrollable growth of parts of the body. Its symptoms vary greatly and affect children physically and emotionally.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...